Cell & Gene Therapy Day

March 5, 2026 | 11:00 AM – 2:00 PM ET

CGT still has plenty of science left to solve, but right now the obstacles for the current cohort are cost, access and speed.

Chinese companies are now developing cheaper alternatives, potentially opening these treatments to a broader patient population. At the same time, the FDA is testing a 'plausible mechanism pathway' designed to accelerate personalized therapies for rare diseases.

We're examining the economics, the regulatory shifts, and the global competition reshaping what's possible at Cell & Gene Therapy Day — including a just-announced session on the FDA's plausible mechanism pathway. See the full agenda and join the conversation.

SPONSORED BY

Questions about registration? Contact our support team.